Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

U.S. spending on multiple sclerosis medicine by type 2010-2014

Expenditure on multiple sclerosis medicines in the United States from 2010 to 2014, by type (in billion U.S. dollars)

by Statista Research Department, last edited Apr 30, 2015
U.S. spending on multiple sclerosis medicine by type 2010-2014 This statistic displays the annual spending on multiple sclerosis medications in the United States from 2010 to 2014, by type. In 2012, 3.9 billion U.S. dollars was spent on multiple sclerosis injectable immunotherapies in the country.
Show more

Expenditure on multiple sclerosis medicines in the United States from 2010 to 2014, by type (in billion U.S. dollars)

Statista Accounts: Access All Statistics. Starting from $588 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$49 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Leading companies trust Statista:
paypalgoogleadobepgsamsungtelekom
Statista is a great source of knowledge, and pretty helpful to manage the daily work.
Christof Baron

Christof Baron
CEO, MindShare Germany

Statistics on "Pharmaceutical industry in Norway "
  • Overview
The most important statistics
  • Production and trade
  • Pharmaceutical turnover
  • R&D, patents and new products
Discover Statista
Need help with using Statista for your research? Tutorials and first steps
Further Content: Statistics, Studies, and Topic Pages
Learn more about how Statista can support your business.
Do you have any questions about our business solutions?

We provide you with detailed information about our Corporate Account.